Cardiovascular drugs most lucrative for Hungary pharma market in 2009, generating revenues of $581.8 million

Having displayed fluctuating growth rates in the years 2005-2009 the Hungary pharmaceuticals market is expected to stabilize and perform low growth rates over the years up to 2014, according to a new report from Venn Research.

The Hungary pharmaceuticals market generated total revenues of $2,706.1 million in 2009, representing a compound annual growth rate (CAGR) of 4.7% for the period spanning 2005-2009. In comparison, the Polish and Czech markets grew with CAGRs of 5.8% and 10% respectively, over the same period, to reach respective values of $6,860.8 million and $2,867.5 million in 2009.

Cardiovascular sales proved the most lucrative for the Hungary pharmaceuticals market in 2009, generating total revenues of $581.8 million, and equivalent to 21.5% of the market's overall value, says Venn Research. In comparison, sales of central nervous system generated revenues of $507.3 million in 2009, equating to 18.7% of the market's aggregate revenues.